{
    "clinical_study": {
        "@rank": "90870", 
        "acronym": "CE/BZA", 
        "arm_group": [
            {
                "arm_group_label": "Non-Obese", 
                "arm_group_type": "Other", 
                "description": "BMI <30 kg/m^2"
            }, 
            {
                "arm_group_label": "Obese", 
                "arm_group_type": "Other", 
                "description": "BMI >= 30 kg/m^2"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess if itraconazole will affect the blood levels of Duavee when they are\n      given together. This study will also assess if a subject's body size affects the blood\n      levels of Duavee."
        }, 
        "brief_title": "Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Generally healthy postmenopausal women, aged 40-64. Intact Uterus\n\n        Exclusion Criteria:\n\n          -  The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing\n             medications within 30 days before study drug administration."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100553", 
            "org_study_id": "B2311065"
        }, 
        "intervention": [
            {
                "arm_group_label": "Non-Obese", 
                "description": "CE 0.45mg/BZA 20mg tablets, single dose", 
                "intervention_name": "CE/BZA", 
                "intervention_type": "Drug", 
                "other_name": "Duavee"
            }, 
            {
                "arm_group_label": "Non-Obese", 
                "description": "Two 100 mg capsules, once daily for 7 days", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug", 
                "other_name": "Sporanox"
            }, 
            {
                "arm_group_label": "Non-Obese", 
                "description": "CE 0.45mg/BZA 20mg tablets, single dose on Day 5", 
                "intervention_name": "CE/BZA", 
                "intervention_type": "Drug", 
                "other_name": "Duavee"
            }, 
            {
                "arm_group_label": "Obese", 
                "description": "CE 0.45mg/BZA 20mg tablets, single dose", 
                "intervention_name": "CE/BZA", 
                "intervention_type": "Drug", 
                "other_name": "Duavee"
            }, 
            {
                "arm_group_label": "Obese", 
                "description": "Two 100 mg capsules, once daily for 7 days", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug", 
                "other_name": "Sporanox"
            }, 
            {
                "arm_group_label": "Obese", 
                "description": "CE 0.45mg/BZA 20mg tablets, single dose on Day 5", 
                "intervention_name": "CE/BZA", 
                "intervention_type": "Drug", 
                "other_name": "Duavee"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estrogens, Conjugated (USP)", 
                "Estrogens", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Postmenopausal Women", 
            "Obese", 
            "Non-obese", 
            "Drug Interaction with Itraconazole", 
            "Pharmacokinetic"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2311065&StudyName=Study%20Evaluating%20Effects%20of%20Multiple-Dose%20Administration%20of%20Itraconazole%20on%20the%20Single%20Dose%20Pharmacokinetics%20of%20Conjugated%20Estrogens/Bazedoxifen"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33125"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33126"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open Label, Two Period, Fixed Sequence, Parallel Group Study to Estimate the Effects of Multiple Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non Obese (BMI <30 Kg/m2) and Obese (BMI \u226530 Kg/m2) Postmenopausal Women", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for BZA, total estrone adjusted for baseline and total equilin.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) for BZA, total estrone adjusted for baseline and total equilin.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100553"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for unconjugated estrone, unconjugated estrone adjusted for baseline, total estrone, and unconjugated equilin.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) for unconjugated estrone, unconjugated estrone adjusted for baseline, total estrone, and unconjugated equilin.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F) for all analytes.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) for all analytes.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F) for all analytes.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "description": "Terminal Phase Elimination Half-Life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Terminal Phase Elimination Half-Life (t1/2) for all analytes.", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}